Repurposed cancer drug holds potential for innovative diabetes treatment A study led by Calibr scientists reveals that an FDA-approved cancer therapy can protect insulin-producing beta cells.
November 13, 2019
LA JOLLA, CA Scientists at Calibr, the drug development arm of Scripps Research, have found what may be the beginnings of a new approach to treating diabetes. And they found it in an unexpected place: a drug that's currently used for a form of breast cancer.
The discovery has jumpstarted efforts to refine the drug for non-cancer diseases and highlights the value of assessing approved medicines for unexpected therapeutic benefits. The study appears in Nature Communications.
The speed of the translation and early proof-of-concept in animals was perhaps the most exciting part of the project, says Matthew Tremblay, PhD, chief operating officer of Calibr and Scripps Research, and a senior author of the study. We were able to find a compound very quickly that we could deploy as a tool in mouse models of diabetes. And because the drug already has FDA approval, we were able to understand its selectivity and pharmacology very readily to drive the program in a preclinical setting.
The drug, neratinib, was shown to protect insulin-producing beta cells in the pancreas. The loss of these cells is a hallmark of both forms of diabetes: type 1, an autoimmune disease that typically emerges early in life; and type 2, the adult-onset form influenced by both genetics and lifestyle. Neratinib is already widely used as a targeted drug for early stage breast cancer, with efficacy for patients whose tumors test positive for the HER2 gene.
Tremblay says the discovery came about through a collaboration facilitated by JDRF (formerly the Juvenile Diabetes Research Foundation), a nonprofit organization dedicated to finding a cure for type 1 diabetes. As part of a platform partnership, JDRF has introduced Calibr to researchers across the globe to translate innovative discoveries into potential new medicines.
The work described in Nature Communications is the result of Calibr's partnership with Kathrin Maedler, PhD, Amin Ardestani, PhD, and their colleagues at the University of Bremen in Germany. The team uncovered that an enzyme known as MST1, which controls cell development and survival, played a key role in activating cell signals that lead to the death or dysfunction of pancreatic beta cells.
The researchers believed that if they could find a way to block or reduce those damaging signals, they may be able to protect beta cells and stave off diabetes. Through prior work together, JDRF was aware of Calibr's unique drug-repurposing and translational capabilities.
Dr. Maedler came to us with an actionable approach for diabetes, Tremblay says. We brought the drug discovery tools to bear, and rapidly found a chemical inhibitor of this particular mechanism that appears to play a key role in the development of disease.
More than 422 million people globally have diabetes, according to the World Health Organization, and an estimated 1.6 million deaths were attributed to the disease in 2016. It is a major cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation.
Calibr identified neratinib using high-throughput screening of drug compounds known as kinase inhibitors, which are often used to treat cancer but also have other therapeutic properties.
Calibr and University of Bremen found that treating diabetic mice for 30 days with neratinib markedly restored beta cell survival and function and prevented severe increases in blood glucose over time. A robust pro-survival effect was also observed in human islets, which are areas of the pancreas that contain beta cells. Prior to the study, neratinib's ability to inhibit MST1 signaling and protect beta cells was not known.
Though the research is just now being published, most of the work was completed before 2017. Calibr has since focused on optimizing neratinib's properties for diabetes and other chronic degenerative diseases. This means letting the drug's anti-cancer properties fall away and diminishing gastrointestinal side effects, among other things.
For chronic, non-terminal diseases where treatment is prolonged, the side effect profile must be pristine, says Weijun Shen, PhD, Calibr's director of metabolic disease and a senior author of the study.
Notably, this project served as one of several inspirations for Calibr in 2018 to build and deploy its ReFRAME drug repurposing collection, an extensive library of nearly all existing, safe small-molecule drugs shown to be appropriate for direct use in humans. The collection offers great potential for finding therapies more quickly and cost-effectively.
Repurposing of FDA-approved drugs has been a topic of great interest amidst the escalating costs of new drug development, particularly in the case of diseases with high-unmet medical need, such as type 1 diabetes, the authors say in the study.
The discovery of neratinib's ability to protect beta cells amounts to an accelerated path to a preclinical proof of concept and a firm basis for follow-up work on next-generation compounds that could add to the treatment options for diabetes, they conclude.
Authors of the article Neratinib protects pancreatic beta cells in diabetes, include Amin Ardestani, Sijia Li, Karthika Annamalai, Blaz Lupse, Shirin Geravandi, Aleksandra Dobrowolski, Shan Yu, Siying Zhu, Tyler D. Baguley, Murali Surakattula, Janina Oetjen, Lena Hauberg-Lotte, Raquel Herranz, Sushil Awal, Delsi Altenhofen, Van Nguyen-Tran, Sean Joseph, Peter G. Schultz, Arnab K. Chatterjee, Nikki Rogers, Matthew S. Tremblay, Weijun Shen and Kathrin Maedler.
The work was supported by JDRF through a Translational Academic Research Partnership.
Diabetes, Obesity and Metabolic Disorders Tr
Most recent headlines
06/10/2025
France T l visions, France's leading broadcaster, has received the 2025 EBU ...
04/09/2025
Monumental Sports & Entertainment (MSE), in collaboration with Dalet, has been a...
30/08/2025
WASHINGTON The Federal Communications Commission has adopted its FY 2025 Regulatory Fees Order that establishes the regulatory fee rates for the broadcast stati...
29/08/2025
Australian Red Cross and SBS launch training to help workplaces in the fight aga...
29/08/2025
The National Film and Video Foundation (NFVF), an agency of the Department of Sp...
29/08/2025
L3Harris Technologies has concentrated decades of expertise across the entire enterprise to develop affordable and reliable best-of-breed solutions to rapidly c...
29/08/2025
BURBANK, Calif. The CW Network and the Pac-12 Conference have announced a new media rights deal that will extend their broadcast partnership beginning with the ...
29/08/2025
NEW YORK Gracenote has released a new analysis of its global video dataset showing that the number of FAST channels grew nearly 14% from Q1 2025 and 76% since 2...
29/08/2025
SAN JOSE, Calif. Harmonic has announced a series of improvements to its live sports streaming solution that the company said will improve fan engagement, protec...
29/08/2025
NEW YORK and LOS ANGELES Fox Corp. and YouTube TV last night announced a renewal of the full portfolio of Fox networks, including Fox News Channel, Fox Business...
29/08/2025
Budapest, Hungary, August 2025 - The integration of Microsoft Teams Rooms (MTR) with Lightware's Taurus universal matrix switchers delivers a new level of f...
29/08/2025
Frequency, the engine behind many of the world's best-known streaming television channels, today announced it will launch Studio Live, a next-generation uni...
29/08/2025
In an era when AI and cyber resilience are essential, Scality will mark the 10th anniversary of Scality Day on October 16, 2025 in Paris. This flagship global e...
29/08/2025
Disguise's In-House Creative and Technical Teams Pre-Visualised, Programmed and Delivered Content for the Experience, All Powered by EX 3+
Technology solu...
29/08/2025
Disguise will be demonstrating the latest workflows for TV, film and live events on a number of partner booths at the show
Disguise, the industry-leading tech...
29/08/2025
STOCKHOLM, Sweden Accedo will showcase Accedo Compose, its AI agent-powered modular orchestration layer that assists streaming providers in transitioning client...
29/08/2025
LOS ANGELES Cineverse has announced that it is working with Xperi to bring four of its streaming channels to automobiles for the first time as part of the DTS A...
29/08/2025
DALLAS & ATLANTA Gray Media has announced an agreement with the sports streaming service Victory+ to simulcast 17 Dallas Stars NHL games in 15 television market...
29/08/2025
NEW YORK AND CULVER CITY Comcast NBCUniversal and Amazon have announced new and extended distribution agreements that will expand the content available on their...
29/08/2025
FOOTHILL RANCH, Calif. RED Digital Cinema will feature its Cine-Broadcast Module supporting live broadcast workflows during IBC2025, Sept. 12-15, at the RAI Ams...
29/08/2025
29 Aug 2025
Kyivstar Rings Opening Bell at Nasdaq Marking Landmark Listing and ...
29/08/2025
More than half of all NFL games live on Sky for the first timeFriday 29 August 2025
Sky Sports has announced a new three-year deal with the NFL, extending its ...
29/08/2025
Back to All News
RIV4LRIES: The Trailer of the New Series With Samuele Carrino ...
29/08/2025
Get ready for an inspiring and emotional insight into the world of competitive Irish dancing with My Story: Tomi Champion of the World airing on RT 2 this monda...
29/08/2025
RT has today announced that David McCullagh is to be the new presenter of RT Radio 1's flagship Today programme, which airs every weekday at 10am, replaci...
28/08/2025
By Kristin Feeley, Director, Documentary Film & Artist Programs
If you want to tell untold stories, if you want to give voice to the voiceless, you've got ...
28/08/2025
Directed by Steven Bognar and Julia Reichert, Sundance Institute-supported Amer...
28/08/2025
Corridos have been a cornerstone of M sica Mexicana for generations, telling stories rooted in everyday life. Now, a new chapter is taking shape: motivational c...
28/08/2025
Los corridos han sido un pilar de la M sica Mexicana durante generaciones, contando historias enraizadas en la vida cotidiana. Ahora, un nuevo cap tulo est tom...
28/08/2025
Earlier this month, we promised our Verano Forever party would bring the heat, a...
28/08/2025
L3Harris will provide the Polish F-16V fleet with the Viper Shield electronic warfare system as part of an upgrade program....
28/08/2025
Bilbao, August 26, 2025 - AgileTV, an international television and video technol...
28/08/2025
Ken Wilkinson is an Emmy Awards nominated New York audio engineer who specialises in production sound mixing for film, commercial, episodic and documentary work...
28/08/2025
NEW YORK FuboTV today announced that it will launch Fubo Sports, a skinny bundle that focuses on sports with a subscription price of $56 monthly....
28/08/2025
NEVADA City, Calif. At IBC2025, Sept. 12-15 at the RAI Amsterdam, Telestream will debut its new Global Ingest strategy, introducing a next-generation ingest arc...
28/08/2025
Dr. Rhoda Bernard Releases Groundbreaking Debut Book on Accessible Arts Educatio...
28/08/2025
TAG Video Systems, the leader in software-based IP end-to-end workflow monitoring, deep probing, and real-time visualization, has named Oliver Gappa as Sales Di...
28/08/2025
AI-based voice enhancement will be among a series of innovations making their IBC 2025 debut on the DHD stand B46 in Hall 8 at the RAI Amsterdam Convention Cent...
28/08/2025
Telef nica Servicios Audiovisuales (TSA), the leading system integrator and service provider in the media sector in Spain, with the support of Appear, the globa...
28/08/2025
To fully immerse sailing fans in the world's biggest offshore yacht race, production company, Optical Media turned to LiveU's On-site Production solutio...
28/08/2025
Working with Calrec on its most recent overhaul, radio and television broadcaster, WNED has migrated to a fully IP infrastructure with multiple Type R consoles,...
28/08/2025
Cleeng, the Subscriber Retention Management (SRM ) inventor, has unveiled Cleeng Pro, the first-ever direct-to-consumer (D2C) subscription management platform t...
28/08/2025
Zixi, the industry leader in live broadcast-quality video over IP, today announced that French media distribution platform OKAST has selected Zixi to enable rel...
28/08/2025
Solution offers a streamlined, speaker-free architecture to optimize integration with premium external loudspeakers and advanced loudness metering
Nixer Pro Au...
28/08/2025
Cinegy, the premier provider of software-defined television technology, has announced a strategic partnership with Vision One Touch Film Production Services L.L...
28/08/2025
Telestream, a global leader in media workflow technologies, will debut its new Global Ingest strategy at IBC2025, introducing a next-generation ingest architect...
28/08/2025
Tier 1 operator selects Broadpeak to power high-performance, unified CDN solution across Norway, Sweden and Finland
Broadpeak, a leader in streaming and moneti...
28/08/2025
Leading video software provider, Synamedia, today announced that 24 Frames Digital, one of India's leading live event streaming service providers, has chose...
28/08/2025
Meet VisualOn at IBC2025: See What's Next in AI-Powered Video Streaming Join VisualOn at IBC2025 and discover how our AI-driven Optimizer and advanced media...
Repurposed cancer drug holds potential for innovative diabetes treatment A study led by Calibr scientists reveals that an FDA-approved cancer therapy can protect insulin-producing beta cells. 
